Talks are underway regarding a potential $400bn mega-merger involving Pfizer, AstraZeneca, and Bristol-Myers Squibb.

The entities involved

• Pfizer →

  American multinational pharmaceutical and biotechnology corporation

  • Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Mon 05:00
  • MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
• AstraZeneca →

  British-Swedish pharmaceutical company

  • AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
  • Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Sat 18:52
• Bristol-Myers Squibb →

  American pharmaceutical company

  • Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
  • FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09

Related events

• Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.Aug 25
• Collaboration revenue realization from Pfizer and GSK backing royalty financing for Spero Therapeutics.Aug 20
• Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.Jun 8
• Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.Aug 26
• Pfizer acquired Biohaven Pharmaceuticals, Seagen, and Arena Pharmaceuticals in transactions dating back to 2022.Jun 27